 |
|
Limited expression of TLR9 on T cells and its functional consequences in patients with nonalcoholic fatty liver disease
Nadia Soledad Alegre, Cecilia Claudia Garcia, Luis Ariel Billordo, Beatriz Ameigeiras, Daniel Poncino, Javier Benavides, Luis Colombato, Alejandra Claudia Cherñavsky
Clin Mol Hepatol. 2020;26(2):216-226. Published online 2019 Dec 5 DOI: https://doi.org/10.3350/cmh.2019.0074
|
|
Citations to this article as recorded by
 Gut microbiota in MAFLD: therapeutic and diagnostic implications
Waleed Alghamdi, Mahmoud Mosli, Saleh A. Alqahtani
Therapeutic Advances in Endocrinology and Metabolism.2024;[Epub] CrossRef Role of pattern recognition receptors in the development of MASLD and potential therapeutic applications
Lili Yu, Feifei Gao, Yaoxin Li, Dan Su, Liping Han, Yueming Li, Xuehan Zhang, Zhiwei Feng
Biomedicine & Pharmacotherapy.2024; 175: 116724. CrossRef Toll‐like receptors in health and disease
Kunyu Wang, Hanyao Huang, Qi Zhan, Haoran Ding, Yi Li
MedComm.2024;[Epub] CrossRef DNA sensors in metabolic and cardiovascular diseases: Molecular mechanisms and therapeutic prospects
Hyosang Kwak, Ein Lee, Rajendra Karki
Immunological Reviews.2024;[Epub] CrossRef Decoding the role of immune T cells: A new territory for improvement of metabolic‐associated fatty liver disease
Jia Liu, Mingning Ding, Jinzhao Bai, Ranyi Luo, Runping Liu, Jiaorong Qu, Xiaojiaoyang Li
iMeta.2023;[Epub] CrossRef Overview of Cellular and Soluble Mediators in Systemic Inflammation Associated with Non-Alcoholic Fatty Liver Disease
Patrice Marques, Vera Francisco, Laura Martínez-Arenas, Ângela Carvalho-Gomes, Elena Domingo, Laura Piqueras, Marina Berenguer, Maria-Jesus Sanz
International Journal of Molecular Sciences.2023; 24(3): 2313. CrossRef Peripheral immune cells in NAFLD patients: A spyhole to disease progression
Shuang-Zhe Lin, Jian-Gao Fan
eBioMedicine.2022; 75: 103768. CrossRef Toll-like receptors and metabolic (dysfunction)-associated fatty liver disease
Shaghayegh Khanmohammadi, Mohammad Shafi Kuchay
Pharmacological Research.2022; 185: 106507. CrossRef Immune–metabolic interactions in homeostasis and the progression to NASH
Joanne A. Hoogerland, Bart Staels, David Dombrowicz
Trends in Endocrinology & Metabolism.2022; 33(10): 690. CrossRef TLR9: A friend or a foe
Mona M. Saber, Nada Monir, Azza S. Awad, Marwa E. Elsherbiny, Hala F. Zaki
Life Sciences.2022; 307: 120874. CrossRef TLR9 in MAFLD and NASH: At the Intersection of Inflammation and Metabolism
Christopher R. Shepard
Frontiers in Endocrinology.2021;[Epub] CrossRef Serum milk fat globule-EGF factor 8 protein as a potential biomarker for metabolic syndrome
Han Ah Lee, Jihwan Lim, Hyung Joon Joo, Young-Sun Lee, Young Kul Jung, Ji Hoon Kim, Hyunggin An, Hyung Joon Yim, Yoon Tae Jeen, Jong Eun Yeon, Do-Sun Lim, Kwan Soo Byun, Yeon Seok Seo
Clinical and Molecular Hepatology.2021; 27(3): 463. CrossRef Toll-like receptor 1 as a possible target in non-alcoholic fatty liver disease
Anja Baumann, Anika Nier, Angélica Hernández-Arriaga, Annette Brandt, Maria J. Lorenzo Pisarello, Cheng J. Jin, Esther Pilar, Amélia Camarinha-Silva, Jörn M. Schattenberg, Ina Bergheim
Scientific Reports.2021;[Epub] CrossRef Does limited expression of toll-like receptor 9 actually contribute to T cell activation and liver damage in nonalcoholic steatohepatitis?
Hyuk Soo Eun
Clinical and Molecular Hepatology.2020; 26(2): 236. CrossRef Limited expression of toll-like receptor 9 on T cells and its functional consequences in patients with nonalcoholic fatty liver disease
Jung Hwan Yu
Clinical and Molecular Hepatology.2020; 26(2): 240. CrossRef Toll-like receptor 9, a possible blocker of non-alcoholic steatohepatitis?
Soung Won Jeong
Clinical and Molecular Hepatology.2020; 26(2): 185. CrossRef
|